Dr Thomas Powles
I lead a translational oncology group that focuses on male genitourinary cancer (GU) cancer and renal cancer. I lead a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection. Alongside these trials, the research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy. Currently the group focuses on HER 1-4, FGF-2 and Src in bladder and renal cancer.
I qualified from St Bartholomew’s Medical School in 1996 and trained in medical oncology at Imperial College. I completed post-graduate training in oncology in 2005 and received an MD from the University of London in 2006. My thesis was in mechanisms of resistance to therapy in urology cancers.
Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W, Wilson P, Sanitt A, Oliver T, Powles T. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer. 2010 May 11. 20564115
Matakidou A, Mutsvangwa K, Ansell W, Lim L, Powles TB, Oliver RT, Shamash J. Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group. Ann Oncol. 2010 Jun 7. 20530199
Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T, Xue L, McIntyre A, Shan L, Powles T, Oliver RT, Young BD, Shipley J, Berney DM, Joel SP, Lu YJ. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010 Jun;176(6):2607-15. 20395447
El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Barthel F, Machiels JP, Patel P, Kreuser ED, Hawkins RE. Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer. 2010 Mar;46(5):859-62. 20167476
For additional publications, please click here.
The translational oncology group sits within the Centre for Experiment Cancer Medicine. It consists of clinical trial coordinators and assistants, research nurses, a clinical team, lab technicians and PhD students In all 9 staff (excluding the doctors) fall within this group.
- NCRN bladder cancer CSG
- NCRN renal cancer CSG
- NCRN translational oncology group
- NCRN CRPC studies group.
- EORTC-GU executive committee
- ESMO faculty for GU cancer.
- Editorial board of Clinical Genitourinary Cancer
- Co chair of trans Atlantic bladder cancer consortium
- International guidelines for testis cancer and renal cancer